GlassScriptPhysician profile
Ahmed O Giwa
NPI 1528406840
$2,375.25
in general payments reported to CMS, 2019-2025
20 companies · $677 in 2025
The $677 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $314 · 2021: $625 · 2022: $143 · 2023: $192 · 2024: $303 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099 · Education: $72.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.18 |
| Education | $72.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $432.49 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $302.60 | 2019-2022 | |
| Amgen INC. | $252.61 | 2019-2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $233.81 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $213.99 | 2020-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $188.88 | 2020-2025 | Vafseo |
| Vifor Pharma, INC. | $181.61 | 2020-2023 | Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $164.76 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $108.61 | 2021-2024 | Rayaldee |
| Alnylam Pharmaceuticals INC. | $43.89 | 2021 | |
| Travere Therapeutics, INC. | $42.03 | 2021-2024 | |
| Ardelyx, INC. | $40.61 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $35.40 | 2024-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $32.72 | 2021-2023 | Gattex |
| Mallinckrodt Enterprises LLC | $23.52 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $20.33 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.48 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $15.90 | 2025 | Ultomiris |
| Horizon Therapeutics Plc | $11.95 | 2019 | |
| Glaxosmithkline, LLC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Giwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.